Reckitt's flu-driven sales hike is nothing to sneeze at; Novartis wins FDA nod for combo glaucoma drug;

 @FiercePharma: To expand HPV vaccination, U.S. public health types should take hints from their Aussie counterparts. Report | Follow @FiercePharma

 @EricPFierce: Alcohol dependence drug Selincro may provide some relief for Lunbeck's Lexapro hangover. Story | Follow @EricPFierce

> The severe U.S. flu season helped fuel a 7% increase in revenues at Reckitt Benckiser, which makes throat lozenges and decongestants; first-quarter sales amounted to £2.52 billion, or $3.8 billion. Report

> Novartis' ($NVS) Alcon unit won FDA approval for Simbrinza Suspension, an eye drop that combines two glaucoma-fighting ingredients. Report

> Elan ($ELN) rejected Royalty Pharma's latest buyout offer, saying $11.25 per share "substantially undervalues the company." Report

> GlaxoSmithKline ($GSK) and Theravance ($THRX) submitted their lung drug Anoro Ellipta for approval in Japan, on the heels of a favorable vote from an FDA advisory panel in the U.S. Report

> Ireland launched its first preferred drugs list, asking doctors to prescribe lansoprazole for gastric reflux and simvastatin to reduce cholesterol, rather than other, more expensive drugs. Report

Medical Device News

 @FierceMedDev: Medtronic teams up with ARCA for a-fib trial. More | Follow @FierceMedDev

 @MarkHFierce: Device and Dx companies are seeing a softening in demand, even with the health reform law still ramping up. Article | Follow @MarkHFierce

 @DamianFierce: As it prepares to go public, Quintiles pulled in $927M in revenue last quarter, 4.2% growth. More | Follow @DamianFierce

> BAROnova's anti-obesity device aces early trial. Story

> Avinger wins $40M commitment backing PAD catheter rollouts. More

Biotech News

 @FierceBiotech: AstraZeneca works both sides of the Atlantic in forging new cancer drug deals. More | Follow @FierceBiotech

 @JohnCFierce: India's clinical trial industry shrivels in wake of safety controversy. Report | Follow @JohnCFierce

 @RyanMFierce: Eli Lilly targets journos on Twitter and Facebook as pharma coverage goes social. Story | Follow @RyanMFierce

> Bristol-Myers rebounds on hep C front with new Merck partnership. News

> AstraZeneca and Boston biotech unite to blast cancer with a nanotech drug. Story

CRO News

> Quintiles' revenue jumps 4.2% in Q1. News

> Indian clinical trials plunge amid increased scrutiny. Article

> Ex-Aptuit researcher jailed over falsified trial results. Story

> Covance bets on Singapore with central lab expansion. More

> GSK, Allergan marred by CMO setbacks. News

Biotech IT News

> Eli Lilly targets journos on Twitter and Facebook as pharma coverage goes social. More

> Multiple myeloma data project could drive innovation. Article

> TEDMED lifts ViS above eClinical throng. Story

> Top 10 Biotech IT Investments in the past year. Special report

And finally ... The new strain of bird flu that has killed 20 people in China already has the genetic diversity of H7 strains that caused much larger outbreaks. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.